title: Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
authors.affiliation: Canadian MS Clinics Network, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Oger
authors.forename: M
authors.initials: M
authors.lastname: Freedman
mesh_terms: D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009462:Neurology / Q000592:standards; D010455:Peptides / Q000627:therapeutic use*
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta